Company Overview
Callan JMB Inc., through its subsidiary, Coldchain Technology Services, LLC provides thermal management logistics solutions to the life sciences industry in United States. It offers logistics solutions and services utilized for frozen shipping in the life sciences industry, including personalized medicine, cell therapies, stem cells, cell lines, vaccines, diagnostic materials, semen, eggs, embryos, cord blood, organs, biopharmaceuticals, infectious substances, and other commodities. The company also provides emergency preparedness services, which includes managing their building sites, medical stockpiles of equipment, and supplies and responding to state or local emergencies; specialty temperature-regulating packaging; technical services; and advanced monitoring sentry technology. In addition, the company engages in oil and gas development business. Callan JMB Inc. has strategic partnership with Alabama State University to advance the United States pharmaceutical manufacturing and supply chain resilience. The company was founded in 2006 and is headquartered in Spring Branch, Texas.
Recent Developments
- Dec 2025 Revenue of $5.72M (-12.8% YoY); net profit $-7.97M.
- Trailing 12 Months Year-on-year growth — revenue -17.4%.
- 5-Year Trend Long-term compounding — revenue CAGR -34.2%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | -34.16% |
| 1 Year: | -17.40% |
Stock Price Performance
| 1 Year: | -51.79% |
| 6 Months: | +30.86% |
| 3 Months: | +198.57% |
| 1 Month: | +45.86% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMAAbove
- Price vs 200-DMAAbove
- Golden Cross5d ago
- RSI (14)58.02 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
- Revenue declined at -34.2% CAGR over 5 years.
- Trading 56.0% below its 52-week high.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Industrials).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | CJMB Callan JMB Inc. | 2.29 | -1.15 | $13.17M | 0.00% | - | - | -34.16% | - |
| 2 | SPCX Space Exploration Technologies Corp. R3KAIDEFENCE | 153.47 | -139.52 | $1.16T | 0.00% | -3.22% | -11.95% | 34.08% | -3.34% |
| 3 | CAT Caterpillar Inc. SPXR3K | 822.48 | 35.47 | $378.07B | 0.79% | 17.98% | 56.97% | 2.29% | 5.24% |
| 4 | GE GE Aerospace SPXR3KDEFENCE | 334.91 | 39.40 | $347.49B | 0.60% | 9.52% | 48.23% | -7.42% | -5.36% |
| 5 | RTX RTX Corporation SPXR3KDEFENCE | 198.81 | 35.06 | $267.95B | 1.51% | 8.28% | 12.27% | 2.61% | 2.62% |
| 6 | GEV GE Vernova Inc. SPXR3KAI | 971.31 | 27.86 | $258.69B | 0.22% | 6.30% | 82.58% | 8.68% | - |
| 7 | DE Deere & Company SPXR3K | 680.73 | 37.88 | $183.54B | 0.95% | 12.53% | 18.24% | 3.43% | 5.10% |
| 8 | UNP Union Pacific Corporation SPXR3K | 288.45 | 23.38 | $171.36B | 2.01% | 15.22% | 39.70% | 2.30% | 7.77% |
| 9 | BA The Boeing Company SPXR3KDEFENCE | 210.73 | 75.80 | $166.43B | 0.00% | -9.01% | - | 1.67% | -3.28% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|
| Revenue | 1.79M | 1.99M | 1.44M | 1.45M | 1.67M | 1.45M | 1.11M |
| Gross Profit | 717.58K | 962.22K | 464.44K | 615.94K | 643.87K | 493.31K | 427.24K |
| Operating Income | -87.46K | -133.42K | -780.98K | -1.24M | -1.40M | -1.88M | -1.70M |
| Net Income | -81.13K | -112.48K | -804.99K | -1.24M | -1.40M | -2.73M | -3.22M |
| Diluted EPS | -0.03 | -0.04 | -0.27 | -0.59 | -0.31 | -0.61 | -0.32 |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|
| Revenue | 13.20M | 6.56M | 5.72M |
| Gross Profit | 5.65M | 2.56M | 2.10M |
| Operating Income | 2.20M | -2.27M | -7.03M |
| Net Income | 2.18M | -2.29M | -7.97M |
| Diluted EPS | - | -0.87 | -1.82 |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|
| Total Assets | - | 9.71M | 5.08M | 5.78M |
| Total Equity | 14.01M | 8.80M | 3.17M | 2.33M |
| Cash & Equivalents | - | 5.16M | 2.10M | 2.13M |
| Total Liabilities | - | 910.27K | 1.91M | 3.45M |
| Current Liabilities | - | 769.71K | 1.27M | 1.41M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|
| Operating Cash Flow | 7.00M | 540.35K | -4.55M |
| Investing Cash Flow | -490.02K | -46.17K | -616.90K |
| Financing Cash Flow | -7.54M | -3.55M | 5.20M |
| Capital Expenditure | -490.02K | -46.17K | -616.90K |
| Free Cash Flow | 6.51M | 494.19K | -5.16M |
| Dividends Paid | 7.40M | 3.33M | - |
Ratios (Annual)
Figures in %.
| Metric | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|
| Gross Margin % | 42.8% | 39.1% | 36.8% |
| Operating Margin % | 16.7% | -34.7% | -122.9% |
| Net Margin % | 16.5% | -34.9% | -139.2% |
| ROE % | 24.8% | -72.3% | -342.2% |
| ROCE % | 24.6% | -59.7% | -161.3% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Creative Planning | 4.51% | 255.69K | $582.98K |
| 2 | Bard Associates Inc. | 4.05% | 229.25K | $522.69K |
| 3 | Citadel Advisors Llc | 0.57% | 32.09K | $73.16K |
| 4 | Axxcess Wealth Management, LLC | 0.44% | 25.00K | $57.00K |
| 5 | Geode Capital Management, LLC | 0.28% | 15.67K | $35.73K |
| 6 | Citigroup Inc. | 0.24% | 13.42K | $30.60K |
| 7 | Financial Plan, Inc. | 0.24% | 13.50K | $30.78K |
| 8 | HighTower Advisors, LLC | 0.22% | 12.50K | $28.50K |
| 9 | Xtx Topco Ltd | 0.20% | 11.29K | $25.73K |
| 10 | Vanguard Capital Management LLC | 0.12% | 6.66K | $15.19K |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for CJMB
Callan JMB (CJMB) lines up $75M stock sales at a discount - Stock Titan
<a href="https://news.google.com/rss/articles/CBMipgFBVV95cUxQajNqcktNMGdtcGFzRHpIaE1iU3ozeUd2RUNhTEFuTTFZWHZXanh0ODc1RGVhYzhTZ1o5WEhrbTdGbGM1VnI2OHF5Ny1jeTNxNHBSUzFucG1seWlVdk1FVG9YRm1vZWRpTk51S1pORXZMeTVCR2dWMEk3bm9oT0w5RE1wNFhRZURNaFYzSm…
Callan JMB Announces Board Change Amid Pending Acquisition - The Globe and Mail
<a href="https://news.google.com/rss/articles/CBMi3gFBVV95cUxNZGgzeDF4WEloUXB2YUpXRF9ZU0R5SllFbW9uNFpjZXFnSzNSVFVnLTBTYTB0TWVKcXRURDBuX1d2bXA5U2RXRmRFaDhfcmZTXy1vM0FrYTJWVFdkbEtBalJuWWFLX2lYVkZzelNzeTdXUHhRYWNXZ1RUcnhUWUl2Vlp0bEVWVVJObHBTM3…
CJMB Stock Rockets On Alabama State Pharma Ecosystem Deal - StocksToTrade
<a href="https://news.google.com/rss/articles/CBMidkFVX3lxTE5ISDJlTG16U1FKdV90QU1qcEt1S1RXMVFQYnFXTlFucW1OVHdTZ3h0Y0NuR09seHBoT3dCU3p2Z0N3eUhVY3N3N2IxSmR4OHJCWU9uZDFFNEJ3eFlWa1pFanpmTGJaS2RCcWRoczRxWGF6X0doeHc?oc=5" target="_blank">CJMB Sto…
$CJMB stock is up 14% today. Here's what we see in our data. - Quiver Quantitative
<a href="https://news.google.com/rss/articles/CBMinwFBVV95cUxNbWtDbmdtQVB0cEhxZndDZHNrZXM5bUl0a2RDS0prN2FvMjQ1VmNXM0JXMmduSlAtbjBSZ285VkxKaVljQVJzNWJsZS1HU0NfQmhiMTc1UG9xZ2NnVVBCelkzS3l2d3FSUzRYU1VvdlNsSlRWVkZISXFqLUQ5dFNsQ3F4VjNyYnJpV19URH…
Callan JMB Inc. Financial Statements – NASDAQ:CJMB - tradingview.com
<a href="https://news.google.com/rss/articles/CBMid0FVX3lxTE5OZTBCWExwMm9ZMFQ5RUhmUVRMSm1mSnFNLWwxMnpDYVJ1U0pjeWxJSmRtQ3NJYmhQaXVEcnpQWWhmckNvMERHdUF2dV9Yd1ZkM1ZBd2pxazdLcGFFbE9jRWJDaWJzM1dzM3JiTmpZR1luNVIwcjNF?oc=5" target="_blank">Callan …
CJMB Stock Soars On Alabama State Pharma Partnership - timothysykes.com
<a href="https://news.google.com/rss/articles/CBMidEFVX3lxTE56eUpBVk5Md3Ezanc5MHRxX2wtUmU2Y2FQRjVKWGdqWmpZazNYV1d4Rk1MMHZmLTN0X3k2dVFWRERuX2xWTFdsSnNKdWVwMEJGUmJ4dzh5YzVCenowbTFwczVIT0UzR3NGd0RhVXFiaFRHblBl?oc=5" target="_blank">CJMB Stock …
CJMB — Frequently Asked Questions
What is the current share price of Callan JMB Inc. (CJMB)?
As of 2026-09-19 21:16 PDT, Callan JMB Inc. (CJMB) trades at $2.29 on NasdaqCM. Its 52-week range is $0.70 to $5.20.
What is the market capitalisation of CJMB?
Callan JMB Inc. (CJMB) has a market capitalisation of $13.17M on NasdaqCM.
What is the P/E ratio of CJMB?
CJMB trades at a trailing price-to-earnings (P/E) ratio of -1.15. The industry average P/E is 26.00. Its price-to-book (P/B) ratio is 18.92.
Is CJMB a good stock to buy?
This page provides a data-driven analysis of Callan JMB Inc. (CJMB), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.